Florigene's inventions disclosed in two granted United States patents, a PCT application and their national phase entries are directed to:
- a method for producing a transformed somatic rose embryo, which expresses an exogenous gene,
- a method for transforming embryogenic, friable, granular rose callus cells with Agrobacterium,
- a method for transforming a rose plant and producing transformed rose plantlets, and
- culture media for callus cultivation and somatic embryo maintenance.
An additional protocol is disclosed to obtain somatic embryos out of a mature somatic tissue, a stamen filament and a leaf explant. These protocols are not limited to transformed tissues.
A new United States patent application has been filed by Florigene. Unlike the granted United States patents, the application describes Agrobacterium-mediated transformation of rose callus cells, without specifying the origin of the callus.
Florigene was founded as a joint venture between DNA Plant Technology Co. (now called S&G Seeds) and Rabobank Biotech Venture Fund, the former also listed as an assignee in the PCT application.
The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to firstname.lastname@example.org.